Your browser doesn't support javascript.
loading
A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment.
Song, Jen-Shin; Chang, Chih-Chun; Wu, Chien-Huang; Dinh, Trinh Kieu; Jan, Jiing-Jyh; Huang, Kuan-Wei; Chou, Ming-Chen; Shiue, Ting-Yun; Yeh, Kai-Chia; Ke, Yi-Yu; Yeh, Teng-Kuang; Ta, Yen-Nhi Ngoc; Lee, Chia-Jui; Huang, Jing-Kai; Sung, Yun-Chieh; Shia, Kak-Shan; Chen, Yunching.
Afiliación
  • Song JS; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, Republic of China.
  • Chang CC; Institute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, 30013 Hsinchu, Taiwan, Republic of China.
  • Wu CH; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, Republic of China.
  • Dinh TK; Institute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, 30013 Hsinchu, Taiwan, Republic of China.
  • Jan JJ; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, Republic of China.
  • Huang KW; Institute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, 30013 Hsinchu, Taiwan, Republic of China.
  • Chou MC; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, Republic of China.
  • Shiue TY; Institute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, 30013 Hsinchu, Taiwan, Republic of China.
  • Yeh KC; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, Republic of China.
  • Ke YY; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, Republic of China.
  • Yeh TK; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, Republic of China.
  • Ta YN; Institute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, 30013 Hsinchu, Taiwan, Republic of China.
  • Lee CJ; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, Republic of China.
  • Huang JK; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, Republic of China.
  • Sung YC; Institute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, 30013 Hsinchu, Taiwan, Republic of China.
  • Shia KS; Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, Republic of China; ksshia@nhri.edu.tw yunching@mx.nthu.edu.tw.
  • Chen Y; Institute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, 30013 Hsinchu, Taiwan, Republic of China ksshia@nhri.edu.tw yunching@mx.nthu.edu.tw.
Proc Natl Acad Sci U S A ; 118(13)2021 03 30.
Article en En | MEDLINE | ID: mdl-33753481
Asunto(s)
Antineoplásicos/farmacología; Protocolos de Quimioterapia Combinada Antineoplásica/farmacología; Carcinoma Hepatocelular/tratamiento farmacológico; Neoplasias Hepáticas/tratamiento farmacológico; Receptores CXCR4/antagonistas & inhibidores; Animales; Antineoplásicos/uso terapéutico; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico; Carcinoma Hepatocelular/inmunología; Carcinoma Hepatocelular/patología; Línea Celular Tumoral; Dietilnitrosamina/administración & dosificación; Dietilnitrosamina/toxicidad; Sinergismo Farmacológico; Humanos; Neoplasias Hepáticas/inmunología; Neoplasias Hepáticas/patología; Neoplasias Hepáticas Experimentales/inducido químicamente; Neoplasias Hepáticas Experimentales/tratamiento farmacológico; Neoplasias Hepáticas Experimentales/inmunología; Neoplasias Hepáticas Experimentales/patología; Linfocitos Infiltrantes de Tumor/efectos de los fármacos; Linfocitos Infiltrantes de Tumor/inmunología; Masculino; Ratones; Simulación del Acoplamiento Molecular; Ratas; Receptores CXCR4/metabolismo; Transducción de Señal/efectos de los fármacos; Sorafenib/farmacología; Sorafenib/uso terapéutico; Linfocitos T Citotóxicos/efectos de los fármacos; Linfocitos T Citotóxicos/inmunología; Microambiente Tumoral/efectos de los fármacos; Microambiente Tumoral/inmunología; Macrófagos Asociados a Tumores/efectos de los fármacos; Macrófagos Asociados a Tumores/inmunología; Macrófagos Asociados a Tumores/metabolismo; Ensayos Antitumor por Modelo de Xenoinjerto
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Hepatocelular / Receptores CXCR4 / Neoplasias Hepáticas / Antineoplásicos Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2021 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Hepatocelular / Receptores CXCR4 / Neoplasias Hepáticas / Antineoplásicos Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2021 Tipo del documento: Article País de afiliación: China